Bliss GVS Pharma

BLISSGVS.NSPre-clinical

Bliss GVS Pharma is a vertically integrated pharmaceutical company with core strengths in anti-malarials, anti-infectives, and a growing portfolio in other therapeutic areas. The company operates through its manufacturing facilities in India and has established a strong commercial footprint in over 70 countries. Its strategic direction involves expanding its product portfolio through in-house R&D and strategic partnerships, while leveraging its manufacturing capabilities to serve regulated and semi-regulated markets.

Market Cap

$237.2M

Employees

1001-5000

Focus

Biotech

BLISSGVS.NS · Stock Price

USD 210.00+136.70 (+186.49%)

Historical price data

AI Company Overview

Technology Platform

Vertically integrated pharmaceutical manufacturing platform with WHO-GMP/EU-GMP certified facilities for APIs and formulations, focused on complex generics and novel drug delivery systems.

Funding History

Total raised: $10M

IPO$10MUndisclosedJun 15, 2000

Opportunities

Growth opportunities include expanding its generic product portfolio in regulated markets like the US and EU for higher margins, further geographic penetration in under-served African regions, and leveraging its manufacturing infrastructure for contract manufacturing.

Diversification into adjacent therapeutic areas with high demand in emerging markets also presents a significant opportunity.

Risk Factors

Key risks include high dependency on anti-malarial tender business, intense pricing pressure in the generics market, regulatory compliance challenges across multiple geographies, and currency fluctuation risks due to significant export revenue.

Geopolitical instability in key African markets also poses a threat to operations.

Competitive Landscape

Bliss GVS faces competition in anti-malarials from other Indian pharma companies like Ipca Laboratories and global entities. In the broader generics space, it competes with large Indian pharma exporters and local manufacturers. Its differentiation is built on deep expertise in anti-malarial ACTs, an integrated API-formulation model, and strong long-term relationships in target African markets.